Showing 181 - 200 results of 416 for search '(( significant decrease decrease ) OR ( significant ((fold decrease) OR (fold increase)) ))~', query time: 0.40s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186
  7. 187
  8. 188

    Key biological processes and genes are identified in TGF-β1-induced fibrosis via transcriptome analysis. by Dong-Hee Han (140305)

    Published 2024
    “…<b>(A)</b> Differentially expressed genes (DEGs; ≥2 folds, ≥7 normalized data value) significantly altered by TGF-β1 treatment were depicted by a Venn diagram. …”
  9. 189

    Data Sheet 3_Changes in monocyte subsets are associated with an increased risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease.docx by Bianca Hamann (10837137)

    Published 2025
    “…A decrease in classical monocytes [odds ratio (OR): 0.73, p = 0.002] and increases in intermediate (OR: 1.41, p = 0.006) and non-classical monocytes (OR: 1.54, p = 0.030) were associated with a higher risk of AAA. …”
  10. 190

    Data Sheet 2_Changes in monocyte subsets are associated with an increased risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease.docx by Bianca Hamann (10837137)

    Published 2025
    “…A decrease in classical monocytes [odds ratio (OR): 0.73, p = 0.002] and increases in intermediate (OR: 1.41, p = 0.006) and non-classical monocytes (OR: 1.54, p = 0.030) were associated with a higher risk of AAA. …”
  11. 191

    Data Sheet 1_Changes in monocyte subsets are associated with an increased risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease.pdf by Bianca Hamann (10837137)

    Published 2025
    “…A decrease in classical monocytes [odds ratio (OR): 0.73, p = 0.002] and increases in intermediate (OR: 1.41, p = 0.006) and non-classical monocytes (OR: 1.54, p = 0.030) were associated with a higher risk of AAA. …”
  12. 192
  13. 193

    Validation of model predictions of growth during infusion of hypertrophic agonists with and without receptor blockers. by Johane H. Bracamonte (12883844)

    Published 2025
    “…By contrast, the model prediction of nearly equal likelihood that ERA increases or decreases NE-induced growth appears to contradict a significant reported decrease in the only available experimental study [<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1012390#pcbi.1012390.ref121" target="_blank">121</a>]. …”
  14. 194
  15. 195
  16. 196

    Development of a User-Friendly Dynamic Culture System for Decellularized Scaffold-Based Tissue Engineering by Shujuan Fan (8380047)

    Published 2025
    “…Compared to static controls, constructs cultured in our platform exhibited a > 5-fold increase in proliferating (Ki67+) cells and a 32-fold decrease in apoptotic (TUNEL+) cells. …”
  17. 197
  18. 198

    Minimal data set. by Zhaoping Meng (4875040)

    Published 2025
    “…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”
  19. 199

    Fragmentation patterns for Schisandrin A. by Zhaoping Meng (4875040)

    Published 2025
    “…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”
  20. 200

    Chemical structure of a lignan. by Zhaoping Meng (4875040)

    Published 2025
    “…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”